Who we are

In MiMARK we care for Women’s health. We are developing innovative in vitro tests to solve unmet clinical needs. WomEC is our first product in development: the future for endometrial cancer diagnosis.

Our commited team


Marina Rigau
CEO & Co-Founder

Eva Colás,
CSO & Co-Founder

Antonio Gil,
CMO & Co-Founder


Todd Snowden
Business Lead

Jordi Petit
Financial Lead

Anna Fàbregas
Regulatory & Quality Specialist

Melody Janseen
Product Dev. Expert

Eva Coll
Project Lead

Javier Carvajal
Lab technician

Astrid Garcia
Lab technician


Business Advisor

Javier F. Magriña
Medical advisor

Frederic Amant
Medical advisor

Denis Querleu
Medical advisor

ongoing project

The next step for diagnosing
endometrial cancer

Unmet clinical need

Abnormal vaginal bleeding affects 11M women in EU and US yearly. Diagnosis of endometrial cancer is mandatory since 10% of these women will suffer it. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose 31% of patients, and provides an inaccurate diagnosis in 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed.

most common cancer
most deathly cancer

IVD test based on the assessment of 5 protein biomarkers in the uterine fluid


WomEC is an in vitro diagnostic test for EC detection based on the quantification of the expression level of a combination of five proteins in the soluble fraction (no cellular material required) of a pipelle biopsy specimen.

WomEC provides a highly accurate diagnosis (99% sensitivity, 79% specificity, 97% negative predictive value (NPV), and 87% positive predictive value (PPV)) on all subjects undergoing the diagnostic procedure for EC. In addition, WomEC provides information regarding tumor histology for those diagnosed with EC to be used in treatment planning and surgical decision making (pre-operative risk assessment).

WomEC is being developed as an immunoassay test to facilitate the clinical implementation in clinical laboratories.

How will it impact the healthcare system


Less invasive with lower risk of complications and pain when avoiding hysteroscopies

Less waiting time and stress from 1-month to 2-day diagnosis

Increased life expectancy: early diagnosis & optimal surgery

Improved QUALYs: personalized/optimal surgery plan


Accurate & objective diagnosis vs subjective pathology

Faster diagnosis & easy patient management from 1 month to 2-day diagnosis

Rule out benign patients safely send home with no need of hysteroscopy (31% of cases)

Rule in high-risk EC patients to referral centers with optimal surgery plan


Lower annual cost of care when avoiding hysteroscopies

More efficient patient management reduced unnecessary procedures

Two patents filled in 2016 and 2017, now extended in AU, BR, CA US, EU, JP, CH and now accepted in EU Well protected asset
Four clinical retrospective studies in 291 patients using
mass spectrometry (LC-PRM) technology and ELISA assay
Protein accuracy in clinical setting.
International publications:
– Oncotarget 2016, Clin Ca Research 2017, Expert Rev Proteomics. 2018
– Advances in endometrial cancer protein biomarkers for use in the clinic. 2017
– Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. 2017
– Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. 2016
Antibody tests achieved in Research Use Only ELISA Prototype feasibility
Validation of the clinical need +150 gynecologists and pathologists Clinical relevance
Currently developing our own antibodies to develop the prototype assay Prototype development

We seek partners to foster WomEC development,
validation and commercialization

Key Opinion Leaders are supporting WomEC

“WomEC will revolutionize uterine cancer diagnosis in the world”

Javier F. Magrina,
Director Gynecologic Oncology

“From a clinical perspective, the project is expected to benefit the European community”

Frederic Amant,
Head of the gynecology oncology department,
ex-chairman of the ENITEC consortium

Contact us

    Funding sources